The Strategic Advisory Council (SAC), chaired by Dr. Howard Chertkow, brings together a group of people with a diverse set of expertise from the arenas of business, politics, communications, and science in order to:
- Offer advice on how best to present CCNA to various stakeholder groups
- Help with creating links to increase CCNA’s visibility and influence
- Advise on ways to increase CCNA’s sustainability
- Comment on the public perception of CCNA and advise how to position ourselves to have the most positive impact
Mr. Dale Goldhawk
Vice-chairman, Alzheimer’s Disease International; Honorary director, Alzheimer’s Society of Canada
Mr. Dale Goldhawk is a journalist, author and broadcaster with more than 45 years of experience in newspapers, radio, and television. Currently, Dale hosts Goldhawk LIVE, a 90-minute public affairs show on Rogers TV in Toronto. He is also the host of Goldhawk Fights Back, a daily citizen advocacy show on Zoomer radio. Dale was nominated by the Canadian Association of Journalists as one of Canada’s outstanding investigative journalists in 2001; was a Gemini Award nominee for Best TV Reporter in 1996; and a national Radio Award nominee for Best Broadcaster in 1992. In 2005, Goldhawk won a Best Performance award from the Canadian Cable Television Association. He is past president of the Alliance of Canadian Cinema, Television and Radio Artists and the Alzheimer Society of Canada and serves as an elected member of the Board of Directors for Alzheimer’s Disease International. Dale has done extensive volunteer work for Easter Seals Ontario, hosting its telethon for more than 25 years. He is a recipient of both the Queen’s Golden Jubilee Medal and the Queen’s Diamond Jubilee Medal, in recognition of his work with charities.
Dr. Kevin Keough, PhD
Executive Director, Alberta Prion Research Institute (APRI)
Dr. Kevin Keough is the Executive Director of the Alberta Prion Research Institute. Kevin is responsible for making recommendation to the CEO of AI Bio regarding the ultimate decision making of the institute. People turn to him when they are seeking advice on how to approach AI Bio and other organizations for funding. His educational background includes undergraduate and graduate degrees in biochemistry from the University of Toronto, a PhD in biochemistry, and time spent performing postdoctoral physical biochemistry work in England. Prior to joining the Alberta Prion Research Institute, Dr. Keough held various positions within the research sector: President and CEO of the Alberta Heritage Foundation for Medical Research, the first Chief Scientist at Health Canada in Ottawa, and the first Vice-President of Research and International Relations at the Memorial University of Newfoundland. He is also co-founder and President of NovaLipids Inc., the Principal of Kevin Keough Consulting Inc., and a Fellow of the Canadian Academy of Health Sciences. Dr. Keough also is a member of the Boards of Directors of Genome Alberta, Genome Atlantic, PrioNet Canada and Science Medi Centre of Canada. He has served as a consultant to national and international research organizations, the pharmaceutical industry and to various levels of government. He continues to actively participate in research activities and is frequently consulted on issues of science and innovation policy and management by academia.
Dr. Ron Keren, MD, FRCPC
Associate Professor, Psychiatry, University of Toronto; Medical Director, Toronto Rehabilitation Institute, Geriatric Rehabilitation Program; Co-Director, UHN Memory Clinic; Head of UHN Seniors Mental Health, University Health Network, Toronto Rehabilitation Institute
Dr. Ron Keren is an associate professor of Psychiatry at the University of Toronto, Medical Director of the Geriatric Rehabilitation Program at the University Health Network-Toronto Rehabilitation Institute and the head of geriatric psychiatry at the University Health Network. Dr. Keren has a clinical and research interests in neurocognitive disorders. He is the co-director of the University Health Network Memory Clinic and staff psychiatrist on the Geriatric Psychiatry inpatient unit at the Toronto Rehabilitation Institute where individuals with advanced dementia with behavioural disorders are assessed and treated. He has been the principal investigator for a number of randomized clinical drug trials exploring novel therapeutic approaches for the treatment of Alzheimer’s disease. Dr. Keren is the founder and president of the Canadian Colloquium on Dementia, a non-profit corporation that runs a biennial national conference on dementia; The Canadian Conference on Dementia (CCD). The conference promotes knowledge transfer from national and international researchers in the field of dementia to a broad range of frontline clinicians providing care to individuals with dementia and their families.
Mr. JD Miller
JD Miller’s business career spans a 30 year period in the areas of strategic planning and corporate finance providing advisory services primarily to public companies. Mr. Miller is active in sport and health across Canada through his leadership of B2ten and its social enterprise, Active for Life. B2ten is a unique consortium of Canadian businessmen mobilized to support Canadian athletes. Currently he sits on the board of directors and audit committee of Tourisme Montréal, the McGill University Health Centre Foundation and Montreal’s 375th Celebrations. He is a recipient of Canada’s Meritorious Service Cross.
Mr. Barry Picov, BSc
Co-founder, Robin and Barry Picov Family Foundation
Mr. Barry Picov holds an Honors B.Sc. Degree in Agriculture from The University of Guelph. He is presently the COO of Ajax Downs Raceway and Casino. Barry’s expertise is in land development. He is a director of the Picov Group of companies since 1985. Barry and his wife Robin were the forerunners to the Youth Crisis Intervention Team at the Centre for Addiction and Mental Health (CAMH). This initiative raised $1.4 million dollars and was implemented at CAMH as of 2013. Mr. Picov held a board position with Ve’ahavta from 2005 to 2011. He now sits on the CCNA oversight committee for the Canadian Institutes of Health Research. The Robin and Barry Picov Family Foundation and the Picov Family have made significant contributions to numerous organizations over several decades.
Dr. David Reynolds, PhD
Chief Scientific Officer, Alzheimer Research UK (ARUK)
Dr. David Reynolds is the Chief Scientific Officer of Alzheimer’s Research UK, which is UK’s leading research charity aiming to defeat dementia. Previously David worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain. David’s external work included representing Pfizer at EFPIA (European Federation of Pharmaceutical Industries and Association) for Europe’s Innovative Medicines Initiative (IMI) and coordinating Pfizer’s participation in over 30 projects. He has served as a member of the Medical Research Council’s Neuroscience and Mental Health Board and on the Scientific Advisory Board of a pain-focussed biotech. David holds a BA in Natural Sciences and a PhD in Neuropharmacology both from the University of Cambridge.